E
Bio-Rad Laboratories, Inc.
BIO
$275.60
-$2.61-0.94%
E
Sell
4/11/2024Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to E+ from D- on 4/11/2024 due to a decline in the volatility index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to E+ from D- on 4/11/2024 due to a decline in the volatility index.
D
Sell
3/21/2024Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D- from E+ on 3/21/2024 due to an increase in the volatility index and total return index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D- from E+ on 3/21/2024 due to an increase in the volatility index and total return index.
E
Sell
3/6/2024Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to E+ from D- on 3/6/2024 due to a decline in the volatility index and solvency index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to E+ from D- on 3/6/2024 due to a decline in the volatility index and solvency index.
D
Sell
2/16/2024Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D- from E+ on 2/16/2024 due to an increase in the valuation index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D- from E+ on 2/16/2024 due to an increase in the valuation index.
E
Sell
10/30/2023Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to E+ from D- on 10/30/2023 due to a decline in the valuation index, volatility index and total return index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to E+ from D- on 10/30/2023 due to a decline in the valuation index, volatility index and total return index.
D
Sell
10/26/2023Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D- from E+ on 10/26/2023 due to an increase in the volatility index and valuation index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D- from E+ on 10/26/2023 due to an increase in the volatility index and valuation index.
E
Sell
10/11/2023Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to E+ from D- on 10/11/2023 due to a decline in the volatility index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to E+ from D- on 10/11/2023 due to a decline in the volatility index.
D
Sell
9/21/2023Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D- from E+ on 9/21/2023 due to an increase in the total return index, valuation index and volatility index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D- from E+ on 9/21/2023 due to an increase in the total return index, valuation index and volatility index.
E
Sell
9/6/2023Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to E+ from D- on 9/6/2023 due to a decline in the volatility index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to E+ from D- on 9/6/2023 due to a decline in the volatility index.
D
Sell
8/22/2023Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D- from E+ on 8/22/2023 due to an increase in the valuation index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D- from E+ on 8/22/2023 due to an increase in the valuation index.
E
Sell
5/8/2023Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to E+ from D on 5/8/2023 due to a significant decline in the efficiency index, volatility index and valuation index. Net income declined 91.73% from $833.49M to $68.96M.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to E+ from D on 5/8/2023 due to a significant decline in the efficiency index, volatility index and valuation index. Net income declined 91.73% from $833.49M to $68.96M.
D
Sell
4/26/2023Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to D from D+ on 4/26/2023 due to a decline in the volatility index and total return index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to D from D+ on 4/26/2023 due to a decline in the volatility index and total return index.
D
Sell
4/5/2023Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D+ from D on 4/5/2023 due to an increase in the total return index and volatility index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D+ from D on 4/5/2023 due to an increase in the total return index and volatility index.
D
Sell
3/17/2023Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to D from D+ on 3/17/2023 due to a decline in the volatility index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to D from D+ on 3/17/2023 due to a decline in the volatility index.
D
Sell
3/2/2023Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D+ from D on 3/2/2023 due to a substantial increase in the efficiency index and volatility index. Net income increased 607.51% from -$164.23M to $833.49M, and total capital increased 11.91% from $9.83B to $11B.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to D+ from D on 3/2/2023 due to a substantial increase in the efficiency index and volatility index. Net income increased 607.51% from -$164.23M to $833.49M, and total capital increased 11.91% from $9.83B to $11B.
D
Sell
10/28/2022Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to D from D+ on 10/28/2022 due to a significant decline in the efficiency index, total return index and volatility index. Total capital declined 4.67% from $10.31B to $9.83B.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to D from D+ on 10/28/2022 due to a significant decline in the efficiency index, total return index and volatility index. Total capital declined 4.67% from $10.31B to $9.83B.
D
Sell
7/28/2022Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to D+ from C- on 7/28/2022 due to a decline in the total return index and volatility index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to D+ from C- on 7/28/2022 due to a decline in the total return index and volatility index.
C
Hold
7/11/2022Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C- from D+ on 7/11/2022 due to an increase in the total return index and volatility index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C- from D+ on 7/11/2022 due to an increase in the total return index and volatility index.
D
Sell
5/25/2022Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to D+ from C- on 5/25/2022 due to a decline in the volatility index and total return index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to D+ from C- on 5/25/2022 due to a decline in the volatility index and total return index.
C
Hold
4/29/2022Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C- from C on 4/29/2022 due to a significant decline in the valuation index, efficiency index and volatility index. Net income declined 114.13% from -$1.57B to -$3.37B, and total capital declined 16.59% from $13.89B to $11.59B.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C- from C on 4/29/2022 due to a significant decline in the valuation index, efficiency index and volatility index. Net income declined 114.13% from -$1.57B to -$3.37B, and total capital declined 16.59% from $13.89B to $11.59B.
C
Hold
3/7/2022Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C from C+ on 3/7/2022 due to a decline in the volatility index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C from C+ on 3/7/2022 due to a decline in the volatility index.
C
Hold
2/16/2022Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C+ from B on 2/16/2022 due to a significant decline in the growth index, volatility index and solvency index. Earnings per share declined from $129.96 to -$52.592, EBIT declined 31.72% from $155.8M to $106.38M, and operating cash flow declined 31.45% from $230.36M to $157.92M.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C+ from B on 2/16/2022 due to a significant decline in the growth index, volatility index and solvency index. Earnings per share declined from $129.96 to -$52.592, EBIT declined 31.72% from $155.8M to $106.38M, and operating cash flow declined 31.45% from $230.36M to $157.92M.
B
Buy
1/14/2022Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B from B+ on 1/14/2022 due to a decline in the volatility index and total return index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B from B+ on 1/14/2022 due to a decline in the volatility index and total return index.
B
Buy
1/7/2022Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B+ from A- on 1/7/2022 due to a decline in the total return index and volatility index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B+ from A- on 1/7/2022 due to a decline in the total return index and volatility index.
A
Buy
12/21/2021Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to A- from B+ on 12/21/2021 due to an increase in the volatility index, total return index and valuation index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to A- from B+ on 12/21/2021 due to an increase in the volatility index, total return index and valuation index.
B
Buy
12/2/2021Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B+ from A on 12/2/2021 due to a substantial decline in the total return index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B+ from A on 12/2/2021 due to a substantial decline in the total return index.
A
Buy
11/30/2021Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to A from A- on 11/30/2021 due to an increase in the volatility index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to A from A- on 11/30/2021 due to an increase in the volatility index.
A
Buy
11/8/2021Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to A- from B+ on 11/8/2021 due to a noticeable increase in the growth index, volatility index and valuation index. Earnings per share increased from $30.32 to $129.96, operating cash flow increased 48.98% from $154.62M to $230.36M, and EBIT increased 34.33% from $115.98M to $155.8M.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to A- from B+ on 11/8/2021 due to a noticeable increase in the growth index, volatility index and valuation index. Earnings per share increased from $30.32 to $129.96, operating cash flow increased 48.98% from $154.62M to $230.36M, and EBIT increased 34.33% from $115.98M to $155.8M.
B
Buy
10/14/2021Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B+ from B on 10/14/2021 due to a large increase in the total return index, volatility index and valuation index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B+ from B on 10/14/2021 due to a large increase in the total return index, volatility index and valuation index.
B
Buy
9/29/2021Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B from B+ on 9/29/2021 due to a large decline in the total return index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B from B+ on 9/29/2021 due to a large decline in the total return index.
B
Buy
9/9/2021Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B+ from B on 9/9/2021 due to a major increase in the total return index and solvency index. The quick ratio increased from 2.34 to 2.66.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B+ from B on 9/9/2021 due to a major increase in the total return index and solvency index. The quick ratio increased from 2.34 to 2.66.
B
Buy
2/17/2021Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B from B+ on 2/17/2021 due to a large decline in the total return index, growth index and volatility index. Earnings per share declined from $43.64 to $27.8059.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B from B+ on 2/17/2021 due to a large decline in the total return index, growth index and volatility index. Earnings per share declined from $43.64 to $27.8059.
B
Buy
2/11/2021Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B+ from B on 2/11/2021 due to a large increase in the total return index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B+ from B on 2/11/2021 due to a large increase in the total return index.
B
Buy
1/27/2021Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B from B+ on 1/27/2021 due to a large decline in the total return index and solvency index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B from B+ on 1/27/2021 due to a large decline in the total return index and solvency index.
B
Buy
11/16/2020Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B+ from B on 11/16/2020 due to a major increase in the total return index, growth index and efficiency index. EBIT increased 111.33% from $51.34M to $108.5M, operating cash flow increased 47.27% from $92.12M to $135.66M, and net income increased 36.05% from $966.43M to $1.31B.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B+ from B on 11/16/2020 due to a major increase in the total return index, growth index and efficiency index. EBIT increased 111.33% from $51.34M to $108.5M, operating cash flow increased 47.27% from $92.12M to $135.66M, and net income increased 36.05% from $966.43M to $1.31B.
B
Buy
3/4/2020Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B from C+ on 3/4/2020 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 313.85% from -$258.82M to $553.49M, earnings per share increased from -$8.68 to $18.3239, and operating cash flow increased 60.2% from $99.75M to $159.8M.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B from C+ on 3/4/2020 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 313.85% from -$258.82M to $553.49M, earnings per share increased from -$8.68 to $18.3239, and operating cash flow increased 60.2% from $99.75M to $159.8M.
C
Hold
2/19/2020Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C+ from B- on 2/19/2020 due to a major decline in the total return index, valuation index and efficiency index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C+ from B- on 2/19/2020 due to a major decline in the total return index, valuation index and efficiency index.
B
Buy
11/5/2019Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B- from B on 11/5/2019 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $19.86 to -$8.68, net income declined 143.22% from $598.81M to -$258.82M, and operating cash flow declined 35.81% from $155.4M to $99.75M.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B- from B on 11/5/2019 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $19.86 to -$8.68, net income declined 143.22% from $598.81M to -$258.82M, and operating cash flow declined 35.81% from $155.4M to $99.75M.
B
Buy
8/13/2019Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B from B- on 8/13/2019 due to a large increase in the valuation index, efficiency index and solvency index. Debt to equity declined from 0.09 to 0.08, total capital increased 10.93% from $5.54B to $6.15B, and the quick ratio increased from 2.81 to 3.05.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B from B- on 8/13/2019 due to a large increase in the valuation index, efficiency index and solvency index. Debt to equity declined from 0.09 to 0.08, total capital increased 10.93% from $5.54B to $6.15B, and the quick ratio increased from 2.81 to 3.05.
B
Buy
6/27/2019Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B- from B on 6/27/2019 due to a decline in the total return index and growth index. Operating cash flow declined 59.11% from $105.01M to $42.94M, EBIT declined 22.29% from $71.56M to $55.61M, and total revenue declined 10.19% from $616.85M to $553.98M.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B- from B on 6/27/2019 due to a decline in the total return index and growth index. Operating cash flow declined 59.11% from $105.01M to $42.94M, EBIT declined 22.29% from $71.56M to $55.61M, and total revenue declined 10.19% from $616.85M to $553.98M.
B
Buy
4/18/2019Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B from B- on 4/18/2019 due to a large increase in the total return index, valuation index and volatility index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B from B- on 4/18/2019 due to a large increase in the total return index, valuation index and volatility index.
B
Buy
4/3/2019Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B- from B on 4/3/2019 due to a significant decline in the valuation index, efficiency index and solvency index. Net income declined 407.63% from $269.33M to -$828.53M, debt to equity increased from 0.09 to 0.11, and total capital declined 16.5% from $5.34B to $4.46B.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B- from B on 4/3/2019 due to a significant decline in the valuation index, efficiency index and solvency index. Net income declined 407.63% from $269.33M to -$828.53M, debt to equity increased from 0.09 to 0.11, and total capital declined 16.5% from $5.34B to $4.46B.
B
Buy
3/29/2019Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B from B- on 3/29/2019 due to an increase in the total return index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B from B- on 3/29/2019 due to an increase in the total return index.
B
Buy
2/1/2019Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B- from B on 2/1/2019 due to a large decline in the volatility index and total return index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B- from B on 2/1/2019 due to a large decline in the volatility index and total return index.
B
Buy
12/6/2018Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B from B+ on 12/6/2018 due to a large decline in the total return index, volatility index and growth index. Operating cash flow declined 20.02% from $77.86M to $62.28M, EBIT declined 19.41% from $44.39M to $35.78M, and total revenue declined 5.34% from $575.91M to $545.14M.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B from B+ on 12/6/2018 due to a large decline in the total return index, volatility index and growth index. Operating cash flow declined 20.02% from $77.86M to $62.28M, EBIT declined 19.41% from $44.39M to $35.78M, and total revenue declined 5.34% from $575.91M to $545.14M.
B
Buy
10/10/2018Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B+ from A- on 10/10/2018 due to a noticeable decline in the total return index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B+ from A- on 10/10/2018 due to a noticeable decline in the total return index.
A
Buy
10/8/2018Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to A- from A on 10/8/2018 due to a decline in the total return index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to A- from A on 10/8/2018 due to a decline in the total return index.
A
Buy
8/15/2018Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to A from A- on 8/15/2018 due to an increase in the total return index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to A from A- on 8/15/2018 due to an increase in the total return index.
A
Buy
8/14/2018Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to A- from B+ on 8/14/2018 due to a large increase in the growth index, valuation index and volatility index. Operating cash flow increased 92.99% from $40.35M to $77.86M, EBIT increased 6.85% from $41.55M to $44.39M, and total revenue increased 4.42% from $551.52M to $575.91M.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to A- from B+ on 8/14/2018 due to a large increase in the growth index, valuation index and volatility index. Operating cash flow increased 92.99% from $40.35M to $77.86M, EBIT increased 6.85% from $41.55M to $44.39M, and total revenue increased 4.42% from $551.52M to $575.91M.
B
Buy
6/5/2018Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B+ from B on 6/5/2018 due to a noticeable increase in the total return index and volatility index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B+ from B on 6/5/2018 due to a noticeable increase in the total return index and volatility index.
B
Buy
5/15/2018Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B from B- on 5/15/2018 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 748.46% from $77.41M to $656.77M, earnings per share increased from $2.5756 to $21.77, and total capital increased 46.29% from $3.37B to $4.92B.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B from B- on 5/15/2018 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 748.46% from $77.41M to $656.77M, earnings per share increased from $2.5756 to $21.77, and total capital increased 46.29% from $3.37B to $4.92B.
B
Buy
5/11/2018Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B- from C+ on 5/11/2018 due to an increase in the total return index, volatility index and solvency index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B- from C+ on 5/11/2018 due to an increase in the total return index, volatility index and solvency index.
C
Hold
4/18/2018Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C+ from C on 4/18/2018 due to a major increase in the valuation index, growth index and efficiency index. Earnings per share increased from $0.91 to $2.5756, net income increased 182.58% from $27.39M to $77.41M, and operating cash flow increased 144.8% from $28.33M to $69.35M.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C+ from C on 4/18/2018 due to a major increase in the valuation index, growth index and efficiency index. Earnings per share increased from $0.91 to $2.5756, net income increased 182.58% from $27.39M to $77.41M, and operating cash flow increased 144.8% from $28.33M to $69.35M.
C
Hold
11/13/2017Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C from C- on 11/13/2017 due to a noticeable increase in the efficiency index, growth index and total return index. EBIT increased 2,396% from -$2.35M to $53.98M, net income increased 444.05% from $5.04M to $27.39M, and earnings per share increased from $0.17 to $0.91.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C from C- on 11/13/2017 due to a noticeable increase in the efficiency index, growth index and total return index. EBIT increased 2,396% from -$2.35M to $53.98M, net income increased 444.05% from $5.04M to $27.39M, and earnings per share increased from $0.17 to $0.91.
C
Hold
10/18/2017Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C- from C on 10/18/2017 due to a major decline in the total return index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C- from C on 10/18/2017 due to a major decline in the total return index.
C
Hold
9/22/2017Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C from C- on 9/22/2017 due to a large increase in the total return index, volatility index and solvency index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C from C- on 9/22/2017 due to a large increase in the total return index, volatility index and solvency index.
C
Hold
9/7/2017Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C- from C on 9/7/2017 due to a large decline in the total return index, efficiency index and growth index. EBIT declined 108.99% from $26.16M to -$2.35M, net income declined 59.44% from $12.41M to $5.04M, and earnings per share declined from $0.41 to $0.17.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C- from C on 9/7/2017 due to a large decline in the total return index, efficiency index and growth index. EBIT declined 108.99% from $26.16M to -$2.35M, net income declined 59.44% from $12.41M to $5.04M, and earnings per share declined from $0.41 to $0.17.
C
Hold
3/3/2017Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C from C+ on 3/3/2017 due to a large decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.62 to -$0.6992, net income declined 211.76% from $18.41M to -$20.57M, and total capital declined 3.69% from $3.14B to $3.02B.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C from C+ on 3/3/2017 due to a large decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.62 to -$0.6992, net income declined 211.76% from $18.41M to -$20.57M, and total capital declined 3.69% from $3.14B to $3.02B.
C
Hold
2/1/2017Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C+ from B- on 2/1/2017 due to a decline in the growth index, valuation index and volatility index. Operating cash flow declined 33.11% from $77.16M to $51.61M, EBIT declined 23.84% from $36.63M to $27.89M, and total revenue declined 1.55% from $516.78M to $508.75M.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C+ from B- on 2/1/2017 due to a decline in the growth index, valuation index and volatility index. Operating cash flow declined 33.11% from $77.16M to $51.61M, EBIT declined 23.84% from $36.63M to $27.89M, and total revenue declined 1.55% from $516.78M to $508.75M.
B
Buy
8/29/2016Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B- from C+ on 8/29/2016 due to a substantial increase in the growth index, total return index and volatility index. Operating cash flow increased 1,135.92% from -$7.45M to $77.16M, EBIT increased 49.84% from $24.44M to $36.63M, and earnings per share increased from $0.4181 to $0.61.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B- from C+ on 8/29/2016 due to a substantial increase in the growth index, total return index and volatility index. Operating cash flow increased 1,135.92% from -$7.45M to $77.16M, EBIT increased 49.84% from $24.44M to $36.63M, and earnings per share increased from $0.4181 to $0.61.
C
Hold
6/24/2016Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C+ from C on 6/24/2016 due to an increase in the valuation index and volatility index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C+ from C on 6/24/2016 due to an increase in the valuation index and volatility index.
C
Hold
6/8/2016Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C from C+ on 6/8/2016 due to a decline in the valuation index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C from C+ on 6/8/2016 due to a decline in the valuation index.
C
Hold
5/24/2016Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C+ from C on 5/24/2016 due to an increase in the volatility index and total return index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C+ from C on 5/24/2016 due to an increase in the volatility index and total return index.
C
Hold
5/9/2016Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C from C+ on 5/9/2016 due to a major decline in the growth index, valuation index and efficiency index. Operating cash flow declined 120.72% from $35.95M to -$7.45M, net income declined 75.19% from $49.48M to $12.28M, and earnings per share declined from $1.6792 to $0.4181.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C from C+ on 5/9/2016 due to a major decline in the growth index, valuation index and efficiency index. Operating cash flow declined 120.72% from $35.95M to -$7.45M, net income declined 75.19% from $49.48M to $12.28M, and earnings per share declined from $1.6792 to $0.4181.
C
Hold
4/1/2016Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C+ from C on 4/1/2016 due to an increase in the volatility index and valuation index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C+ from C on 4/1/2016 due to an increase in the volatility index and valuation index.
C
Hold
3/17/2016Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C from C+ on 3/17/2016 due to a noticeable decline in the volatility index, total return index and solvency index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C from C+ on 3/17/2016 due to a noticeable decline in the volatility index, total return index and solvency index.
C
Hold
11/6/2015Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C+ from B- on 11/6/2015 due to a substantial decline in the growth index, volatility index and total return index. Earnings per share declined from $0.97 to $0.59, EBIT declined 27.24% from $43.81M to $31.87M, and total revenue declined 7.14% from $506.1M to $469.96M.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C+ from B- on 11/6/2015 due to a substantial decline in the growth index, volatility index and total return index. Earnings per share declined from $0.97 to $0.59, EBIT declined 27.24% from $43.81M to $31.87M, and total revenue declined 7.14% from $506.1M to $469.96M.
B
Buy
10/12/2015Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B- from B on 10/12/2015 due to a large decline in the volatility index and efficiency index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to B- from B on 10/12/2015 due to a large decline in the volatility index and efficiency index.
B
Buy
4/1/2015Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B from B- on 4/1/2015 due to a large increase in the volatility index, total return index and solvency index.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B from B- on 4/1/2015 due to a large increase in the volatility index, total return index and solvency index.
B
Buy
3/5/2015Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B- from C+ on 3/5/2015 due to a substantial increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.39 to $1.3394, EBIT increased 120.78% from $30.24M to $66.76M, and total revenue increased 12.74% from $530.64M to $598.22M.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B- from C+ on 3/5/2015 due to a substantial increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.39 to $1.3394, EBIT increased 120.78% from $30.24M to $66.76M, and total revenue increased 12.74% from $530.64M to $598.22M.
C
Hold
2/27/2015Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C+ from C on 2/27/2015 due to an increase in the valuation index, efficiency index and growth index. Operating cash flow increased 2.93% from $80.9M to $83.27M.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to C+ from C on 2/27/2015 due to an increase in the valuation index, efficiency index and growth index. Operating cash flow increased 2.93% from $80.9M to $83.27M.
C
Hold
5/19/2014Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C from C+ on 5/19/2014 due to a noticeable decline in the growth index, volatility index and valuation index. Earnings per share declined from $1.0391 to $0.23, EBIT declined 65.57% from $59.46M to $20.47M, and total revenue declined 15.48% from $602.64M to $509.34M.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C from C+ on 5/19/2014 due to a noticeable decline in the growth index, volatility index and valuation index. Earnings per share declined from $1.0391 to $0.23, EBIT declined 65.57% from $59.46M to $20.47M, and total revenue declined 15.48% from $602.64M to $509.34M.
C
Hold
5/7/2014Downgrade
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C+ from B- on 5/7/2014 due to a decline in the total return index.
Bio-Rad Laboratories, Inc. (BIO) was downgraded to C+ from B- on 5/7/2014 due to a decline in the total return index.
B
Buy
3/20/2014Upgraded
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B- from C+ on 3/20/2014 due to a major increase in the volatility index, growth index and solvency index. EBIT increased 109.69% from $28.36M to $59.46M, total revenue increased 19.32% from $505.07M to $602.64M, and operating cash flow increased 16.86% from $62.85M to $73.44M.
Bio-Rad Laboratories, Inc. (BIO) was upgraded to B- from C+ on 3/20/2014 due to a major increase in the volatility index, growth index and solvency index. EBIT increased 109.69% from $28.36M to $59.46M, total revenue increased 19.32% from $505.07M to $602.64M, and operating cash flow increased 16.86% from $62.85M to $73.44M.
NYSE
04/25/2024 4:00PM Eastern
Quotes delayed
